.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Clinical Advances in Nasopharyngeal Carcinoma

A panel of experts on nasopharyngeal carcinoma review patient cases and provide comprehensive insights on treatment practices.

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

August 21st 2024

Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.

Clinical Advances in Nasopharyngeal Carcinoma

EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach

EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma

EP. 3: Overview of the JUPITER and POLARIS-2 Trials

EP. 4: Value of PD-L1 Biomarker in NPC

EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab

EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors

EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment

EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma

EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects

EP. 10: Clinical Scenario: Locally Recurrent NPC